Navigation Links
Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period

Sees opportunity to end abusive use of authorized generics during period of exclusivity

PITTSBURGH, June 3 /PRNewswire-FirstCall/ -- Mylan Inc.'s (Nasdaq: MYL) Chief Operating Officer Heather Bresch today testified before the U.S. House of Representatives Judiciary Subcommittee on Courts and Competition Policy concerning patent litigation settlements between branded pharmaceutical companies and generic pharmaceutical companies. During her testimony, Bresch conveyed Mylan's position that the launch of an authorized generic by brand companies during a generic company's 180-day exclusivity period undermines competition and delays timely access to high quality, affordable generic medications for patients, taxpayers, the government and businesses.

The committee's hearing, "Pay to Delay: Are Patent Settlements That Delay Generic Drug Market Entry Anticompetitive?," was called to gather information about the effects of settlements.

Bresch commented: "When it comes to settlements, Congress need look no further than the use and abuse of authorized generics by brand manufacturers. The increase in the number of patent litigation settlements in recent years is directly related to the increased use of authorized generics during the 180-day market exclusivity period. This tactic upsets the natural balance of incentives that Congress intended with its 1984 Hatch-Waxman legislation."

Bresch continued: "Congress has an opportunity to act now to ensure that timely access to affordable generics is offered to patients by restoring the true 180-day exclusivity period. This is even more profound and critical today as Congress deliberates on a regulatory pathway for life-saving generic biologics, treatments that can cost hundreds of thousands of dollars per patient per year."

A complete version of Bresch's written testimony for the subcommittee hearing can be found at

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
2. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
3. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
4. Mylan Confirms Four First-to-File Challenges
5. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
6. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
7. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
Post Your Comments:
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... 2015  Rebiotix Inc. today announced that U.S. ... lead Microbiota Restoration Therapy (MRT) RBX2660 as a ... Clostridium difficile (C diff) infection, a challenging ... deaths in the U.S. annually. 1 Rebiotix ... founded to revolutionize the treatment of debilitating GI ...
(Date:10/12/2015)... , October 12, 2015 ... Dario™ Diabetes Management Solution, today announced its Medical Director, ... case study at MobiHealth,s 5th EAI International Conference ... "Transforming healthcare through innovations in mobile and wireless technologies," ... England from October 14 - 16, 2015. ...
(Date:10/12/2015)... ... October 12, 2015 , ... LifeTrak , a leader in consumer ... the world’s first amphibious fitness tracker that seeks to meet the needs of multi-sport ... heart rate monitoring both in water and on land, making it the ...
Breaking Biology Technology:
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
(Date:9/26/2015)... 26th, 2015  Results of a TactioRPM pilot ... today at the Stanford Medicine X Conference. In ... Dashboards, Connected Health Devices and Pharmacogenomics", Roger ... will explain how senior patients equipped with connected ... pharmacist via the TactioRPM remote patient monitoring platform ...
(Date:9/10/2015)... , Sept. 10, 2015 Report ... New Study Reveals Selling Opportunities and Revenue Prospects ... the future of biologics, especially new drug classes? ... will stay ahead with exclusive market data and ... explore trends, developments, results, opportunities and sales predictions. ...
Breaking Biology News(10 mins):